Obesity has risen dramatically in recent years, making it the biggest risk factor for developing cardiovascular disease, various cancers, and also Diabetes mellitus type 2 (DM2). The association of obesity with the development of DM 2 can be explained, in part, by altered secretion of adipokines by adipose tissue, such as adiponectin, which exhibits anti-inflammatory and insulin-sensitizing. Excess adipose tissue negatively regulates the secretion of adiponectin. Because biomolecular diagnostics are extensive and costly and thus still largely inaccessible to a large portion of the population, the development of new methodologies and reliable and low cost diagnostic tools (which may be implemented by the national health care system - SUS) is essential. In this project we propose the development of devices for detection and quantification of adiponectin, based on the use of nanostructured biosensors and investigation of the relationship of the concentration of this hormone with the health status of patients. This study may possibly provide the early diagnosis of DM 2, through cheaper and faster devices. The project is a pioneering and innovative as the biotech products to be developed can be of great interest to the health industrial complex (CIS), in particular, the sector diagnostic hospital equipment, considered as the pillars of the CIS, and where the country currently presents a greater dependence on foreign technologies. The results may contribute significantly to the Nanomedicine implant their preventive basis in many pathologies, which could significantly impact on the health system of Brazil, emphasizing the potential social aspect of the project.
News published in Agência FAPESP Newsletter about the scholarship: